Latigo Biotherapeutics Closes $345.6M IPO at $18.00 Per Share

summarizeSummary

Latigo Biotherapeutics completed its IPO on August 10, 2026, raising $345.6 million at $18.00 per share, and adopted a new charter authorizing up to 1 billion common shares.

check_boxKey Events · Financing and Capital Events · LTGO

• IPO Completed

  The company sold 19.2 million shares at $18.00 each, generating gross proceeds of approximately $345.6 million before underwriting discounts and expenses.

• Financial Impact

  Substantial capital from the IPO will fund operations and pipeline development, with the offering price near the current market price reflecting strong institutional demand.

• Charter Amendment

  An amended and restated certificate of incorporation was adopted, authorizing 999,999,999 common shares and 10,000,000 preferred shares, which creates significant headroom for future equity issuances.

• Governance Changes

  Effective upon the IPO closing, amended and restated bylaws were adopted, implementing a classified board structure and supermajority voting requirements for certain amendments.

auto_awesomeAnalysis · LTGO · Life Sciences

With the closing of its initial public offering, Latigo Biotherapeutics raised roughly $345.6 million in gross proceeds by selling 19.2 million shares at $18.00 each. The offering price sits just below the current trading price of $18.56, signaling solid institutional demand. A new charter was also adopted, authorizing nearly 1 billion common shares—ample headroom for future capital raises but also a potential dilution risk. For an emerging growth biotech, this cash infusion extends the runway to advance its pipeline, though the newly public structure and large authorized share count mean investors should monitor for future equity offerings.